An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.

Abstract	Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor. Results from the primary analysis of a phase 3, randomized, controlled study showed a statistically significant improvement in progression-free survival for patients receiving panitumumab; however, overall survival was confounded by best supportive care (BSC) patients that crossed over to panitumumab therapy after disease progression. Three post hoc analyses are presented that approximate the panitumumab overall survival treatment effect in both the all-randomized and wild-type (WT) KRAS populations by using the BSC patients with mutant (MT) KRAS as the comparator group to discount the effect of crossover from BSC to panitumumab. The primary post hoc analysis showed a median overall survival of 6.4 months for all KRAS-evaluable patients randomized to panitumumab versus 4.4 months for patients with MT KRAS tumors randomized to BSC, yielding an adjusted hazard ratio (95 % CI) of 0.764 (0.598-0.977). Similar results were observed for the two secondary post hoc analyses. These analyses suggest a positive treatment effect of panitumumab in both the overall and WT KRAS patient populations consistent with an improvement in overall survival relative to BSC.
Authors	Melanie Poulin-Costello, Laurent Azoulay, Eric Van Cutsem, Marc Peeters, Salvatore Siena, Michael Wolf
Journal	Targeted oncology (Target Oncol) Vol. 8 Issue 2 Pg. 127-36 (Jun 2013) ISSN: 1776-260X [Electronic] France
PMID	23625191 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Antineoplastic Agents Panitumumab
Topics	Antibodies, Monoclonal (adverse effects, therapeutic use) Antineoplastic Agents (adverse effects, therapeutic use) Colorectal Neoplasms (drug therapy, genetics, therapy) Cross-Over Studies Disease-Free Survival Female Genes, ras Humans Male Middle Aged Neoplasm Metastasis Palliative Care (methods) Panitumumab Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!